These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32005117)

  • 1. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
    Wang Y; He L; Song Y; Wu Q; Wang H; Zhang B; Ma X
    BMC Womens Health; 2020 Jan; 20(1):17. PubMed ID: 32005117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
    Yu KD; Wu SY; Liu GY; Wu J; Di GH; Hu Z; Hou YF; Chen CM; Fan L; Tang LC; Shen ZZ; Wu KJ; Zhuang ZG; Zhang HW; Shao ZM
    Cancer; 2019 Jul; 125(13):2185-2193. PubMed ID: 30892700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis.
    Ma HF; Shen J; Xu B; Shen JG
    Medicine (Baltimore); 2023 Nov; 102(46):e35928. PubMed ID: 37986364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
    Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
    JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials.
    Huang L; Xu AM
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):327-334. PubMed ID: 28271747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
    van de Loo ME; Andour L; van Heesewijk AE; Oosterkamp HM; Liefers GJ; Straver ME
    Breast Cancer Res Treat; 2024 May; 205(1):5-16. PubMed ID: 38265568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis.
    Zhang T; Feng F; Yao Y; Qi L; Tian J; Zhou C; Dong S; Wang X; Sun C
    J Cell Physiol; 2019 Aug; 234(8):12393-12403. PubMed ID: 30652307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
    Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
    Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2- Breast Cancer.
    Wright JL; Saigal K; Reis IM; Zhao W; Takita C; Ambros T; Saeed AM; Sujoy V; Hurley J
    Am J Clin Oncol; 2017 Oct; 40(5):490-497. PubMed ID: 26017482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
    Gazet JC; Ford HT; Gray R; McConkey C; Sutcliffe R; Quilliam J; Makinde V; Lowndes S; Coombes RC
    Ann Oncol; 2001 May; 12(5):685-91. PubMed ID: 11432629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients.
    Ding Y; Ding K; Yang H; He X; Mo W; Ding X
    PLoS One; 2020; 15(5):e0234058. PubMed ID: 32470093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
    Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
    Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
    Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
    Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
    Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
    Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Feasibility Study of
    Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH
    J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
    Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
    PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.